Cortico-autonomic local arousals and heightened somatosensory arousability during NREMS of mice in neuropathic pain.

Frequent nightly arousals typical for sleep disorders cause daytime fatigue and present health risks. As such arousals are often short, partial, or occur locally within the brain, reliable characterization in rodent models of sleep disorders and in human patients is challenging. We found that the EEG spectral composition of non-rapid eye movement sleep (NREMS) in healthy mice shows an infraslow (~50 s) interval over which microarousals appear preferentially. NREMS could hence be vulnerable to abnormal arousals on this time scale. Chronic pain is well-known to disrupt sleep. In the spared nerve injury (SNI) mouse model of chronic neuropathic pain, we found more numerous local cortical arousals accompanied by heart rate increases in hindlimb primary somatosensory, but not in prelimbic, cortices, although sleep macroarchitecture appeared unaltered. Closed-loop mechanovibrational stimulation further revealed higher sensory arousability. Chronic pain thus preserved conventional sleep measures but resulted in elevated spontaneous and evoked arousability. We develop a novel moment-to-moment probing of NREMS vulnerability and propose that chronic pain-induced sleep complaints arise from perturbed arousability

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Étude des fonctions du récepteur opioïde delta exprimé dans le cerveau antérieur grâce à une approche de knockout conditionnel

Delta opioid receptors (DORs) are G-protein coupled receptors belonging to the opioid system, which play a central role in chronic pain and emotional responses. DORs are strongly expressed in olfactory bulb, cortex, striatum, basolateral nucleus of the amygdala and pons nuclei. Using constitutive gene knockout, we have previously demonstrated the role of DORs in reducingchronic pain (Gaveriaux-Ruff, Nozaki et al. 2011), anxiety-related behaviors and impulsivity(Olmstead,Ouagazzal et al. 2009), regulating locomotor activity (Filliol, Ghozland et al. 2000) and facilitating context learning (Le Merrer, Faget et al. 2012; Le Merrer, Rezai et al. 2013), Although these functions are well-established, neuronal networks and mechanisms underlying DOR-regulated behaviors remain poorly understood. The aim of this thesis work was to identify neuronal populations and brain circuits that support DOR functions. Recent evidence showed that DOR is highly expressed in GABAergic neurons (Scherrer et al.. 2006;Erbs et al., 2012; Rezai et al.. 2012). We therefore developed a conditional knockout mouse line (Dlx-DOR)by breeding floxed DOR gene (Oprd1) with a transgenic Dlx-5/6-Cre mouse line (Monorv et al., 2006) in order to produce a specific deletion of DOR in GABAergic neurons of the forebrain. We first determined brain distribution of delta receptors in Dlx-DOR at mRNA and protein levels. Then, behavioral analysis were performed to assess whether DORs expressed in forebrain GABAergic neurons contribute to the regulation of emotional contrai, locomotor activity as well as epileptogenic effect of SNC80, the prototypal DOR agonist. Finally, we initiated a project focused on DORs detected at the level of BLA.Les récepteurs opioïde delta (DORs) sont des récepteurs couplés aux protéines G et sont fortement exprimés au niveau du bulbe olfactif, du cortex, du striatum, du noyau basolateral de l'amygdala et des noyaux du pons (Mansour et al., 1995; Le Merrer et al., 2009). Les souris mutantes de première génération (souris knockout, délétion totale du gène) ont déjà permis de démontrer que DOR joue un rôle critique dans le contrôle de la douleur chronique (Gavériaux-Ruff et al., 2011), la régulation de l’activité motrice et des réponses émotionnelles (Filliol et al ., 2000) et l’association drogue-contexte (Le Merrer et al., 2011). Le but de notre étude est d’identifier les circuits neuronaux dans lesquels les DORs contrôlent les processus émotionnels et cognitifs. Nous avons développé une lignée de souris de deuxième génération, dans laquelle les récepteurs sont supprimés spécifiquement dans les neurones GABAergiques du cerveau antérieur. Nous avons ensuite étudié le rôle des DORs exprimés par ces neurones dans les réponses émotionnelles, locomotrices et la sensibilité aux crises épileptiques

Testing brown lemurs (Eulemur fulvus) on the reverse-reward contingency task without a modified procedure.

International audienceA common paradigm used to study inhibitory control is the reverse-reward contingency task in which the subject is presented with a choice between two different quantities of food and is rewarded with the non-chosen item. Most animals have problems inhibiting their impulsive choice towards the larger quantity, and need correction procedures to master the reverse-reward task. Recent studies have nonetheless shown that rhesus macaques and white crowned mangabeys were able to master the task without correction procedures after a large number of trials were applied. We previously demonstrated that, similar to other primates tested under the reverse-reward contingency task, lemurs initially showed an impulsive bias towards the larger quantity of food. But following introduction of a large-or-none contingency, all the subjects learned to reliably select the smaller quantity in order to gain access to the larger one. Here, we assessed the possibility that, similar to rhesus macaques and mangabeys, lemurs could master the reverse-reward task, without a modified procedure, by presenting a large number of trials. One of 5 subjects was able to master the task and then generalize performance to novel food arrays

Peripheral nerve injury induces a transitory microglial reaction in the rat infralimbic cortex.

Undeniable evidence shows that microglia in the spinal cord undergo marked reactions following peripheral injuries. However, only rare studies have investigated the possible short and long term microglial reaction in brain regions following peripheral nerve injury and its interspecies specificities. In the present study we examined microglia in subdivisions of the prefrontal cortex in mice and rats, 7days and 42days after spared nerve injury (SNI) of the sciatic nerve. We show that a bilateral increase of microglial density takes place in the infralimbic cortex in rats 7days post-injury (sham vs. SNI, n=5: ipsilateral 35.4% increase of the median, p=0.0317; contralateral 24.9% increase of the median, p=0.0079), without any detectable change in the other investigated regions, namely the anterior cingulate, prelimbic and agranular insular cortices. In mice, no observable difference could be found in any region at both time points, neither using Iba-1 immunostaining nor with CX3CR1-eGFP animals. Our results indicate that a transitory, species-specific and highly regionalized microglial reaction takes place in the prefrontal cortex following peripheral nerve injury

Data from: Characterisation of GFAP-Expressing Glial Cells in the Dorsal Root Ganglion after Spared Nerve Injury

&lt;p&gt;This data&nbsp;pertain to the paper titled "Characterisation of GFAP-Expressing Glial Cells in the Dorsal Root Ganglion after Spared Nerve Injury " by Elena A. Konnova, Alexandru-Florian Deftu, Paul Chu Sin Chung, Marie Pertin, Guylène Kirschmann, Isabelle Decosterd and Marc R. Suter. The name of the data files correspond to the for each figure in the study.&nbsp;The&nbsp;data file in .csv format are organized so that they can easily be opened in R or other analysis language. To understand them and how they are labelled, it is advised to open the figure next to them and find the appropriate panel.&lt;/p&gt;&lt;p&gt;Here are included:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;the representative images of immunohistochemistry for GFAP, IBA1, Ki67, NeuN, ATF3, FABP7, GS, Cx43, Kir4.1, MBP, L1CAM in the dorsal root ganglia (DRG) of hGFAP-CFP mice after spared nerve injury (SNI).&lt;/li&gt;&lt;li&gt;the western blot images of DRG samples and FACS sorted CFP+ cells from the DRG of hGFAP-CFP mice after SNI&lt;/li&gt;&lt;li&gt;the voltage clamp data of GFAP+ cells from DRG of hGFAP-CFP mice after SNI&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&nbsp;&lt;/p&gt